Small Molecule Inhibitors of BAD Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective small molecule modulators targeting Bcl-2-associated death promoter (BAD) proteins, which are crucial for regulating apoptosis and are often phosphorylated in cancer cells, leading to resistance and poor treatment outcomes.
Innovation Solution
Development of novel compounds of general formula (I) that inhibit site-specific BAD phosphorylation without affecting upstream kinases, promoting apoptosis in cancer cells by occupying the protein-protein interface and hydrophobic groove within the Bcl-2/BAD complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule modulators targeting BCL-2 family proteins are used, then apoptosis regulation is improved, but no effective modulators exist for BH3-only proteins like BAD
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that specifically bind to the BAD protein at its hydrophobic groove, preventing BAD phosphorylation and subsequent dimerization with anti-apoptotic BCL-2 family proteins. These compounds act as mediators between the regulatory signal and the apoptotic execution machinery, filling the therapeutic gap for BH3-only protein modulation.
Solution Approach 2:
The invention targets a specific local region of the BAD protein—the hydrophobic groove and protein-protein interface—rather than the entire protein structure. By designing compounds that specifically occupy this local site, the patent achieves selective inhibition of BAD phosphorylation and dimerization without affecting other BCL-2 family members or upstream kinases.
2Reliability
If BAD phosphorylation is inhibited to promote apoptosis, then cancer cell death is enhanced, but selective toxicity against cancer cells versus normal cells must be maintained
Solution Approach 1:
The patent employs compounds with specific local structural features (hydrophobic moieties, aromatic rings, and specific functional groups) that match the hydrophobic groove of BAD protein. This localized structural complementarity enables selective binding to BAD in cancer cells where phosphorylation pathways are dysregulated, while sparing normal cells with intact regulatory mechanisms.
Solution Approach 2:
The invention utilizes compounds that induce parameter changes in the BAD protein's conformational state and phosphorylation status. By altering the phosphorylation state and dimerization equilibrium of BAD, the compounds promote apoptosis selectively in cancer cells where these parameters are already perturbed, creating a therapeutic window between cancer and normal cells.
Data Source
AI summary
The invention relates to compounds of general formula (I): wherein R1, n, R2a, R2b, and R3 are as defined herein. The compounds are inhibitors of Bcl-2-associated death promoter (BAD) phosphorylation and have anti-apoptotic activity and are useful in the treatment of cancer, particularly breast cancer, endometrial cancer, ovarian cancer, liver cancer, colon cancer, prostate cancer or pancreatic cancer.